Jupiter Neurosciences Initiates Patient Enrollment In Its Phase 2a RESET Clinical Study For JOTROL In Parkinson's Disease

Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that patient enrollment is now underway in its Phase 2a RESET clinical trial (NCT07592767) for JOTROL™ (investigational trans-resveratrol micellar formulation) in Parkinson's Disease (PD), with first patient dosing expected in the near term.

Parkinson's Disease affects an estimated 1.1 million people in the United States, with roughly 90,000 new diagnoses annually, and carries an estimated annual U.S. economic burden of $82.2 billion. The global PD treatment market was valued at $5.65 billion in 2024 and is projected to reach $7.58 billion by 2030, growing at a CAGR of about 5.0%. Despite decades of research, no disease-modifying therapies have been approved for PD to date. JOTROL™ is an investigational drug candidate that has not been approved by the FDA or any regulatory authority. It is currently being evaluated for its potential to target underlying biological drivers of neurodegeneration.